• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Nauseef on PSMA-targeted radionuclide-drug conjugate for mCRPC

Commentary
Video

The radionuclide-drug conjugate 225Ac-J591 combines J591, a monoclonal antibody that recognizes PSMA, with actinium-225, a potent alpha emitter.

Jones T. Nauseef, MD, PhD, discusses PSMA-targeted radionuclide-drug conjugate 225Ac-J591. This novel compound combines J591, a monoclonal antibody that recognizes PSMA, with actinium-225, a potent alpha-emitter. Early phase research has shown promise for the investigational agent in patients with metastatic castration resistant prostate cancer (mCRPC). Nauseef is assistant professor of medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, and assistant attending physician at NewYork-Presbyterian Hospital.

Transcript

There are a couple different ways to target PSMA. One is with a small molecule ligand, and the other one would be with a monoclonal antibody. So, J591 is our monoclonal antibody that has terrific targeting on cells that are expressing PSMA, and it helps with internalization into the cell. This monoclonal antibody is going to go throughout the body and with it carry actinium 225, and that is a very potent radionuclide. So, with the antibody going to the sites where you want it to go, it will bring with its payload, which is radionuclide. And an alpha emitter like actinium-225 is very potent.

Patients with mCRPC can have cancer anywhere in their body, and you want to be able to target this. You can do that effectively with an antibody like J591 and bring with it a very potent radionuclide. One of the things that's so nice about the potency of this drug is that it has a very short path length. So, though you're delivering a high energy that even a single hit on a cell can result in double stranded DNA breaks and cell death, the path length is very short. So, your toxicity potentially may be lower because the drug isn't going to get away from where you want it to be. This will be true anywhere that a patient has cancer that can be commonly in the bones, the lymph nodes, but also visceral sites of disease, such as the liver and lungs.

Transcript has been edited for clarity.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
Stephanie Gleicher, MD, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Mature woman with her doctor | Image Credit: © pucko_ns - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.